Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform. We are building a rich pipeline of assets in four therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases.

The Kymouse strains have more base-pairs of the human immunoglobulin genes than any other model. Their performance is exceptional: virtually every mouse responds to challenge, producing high-titre polyclonal antibodies to a variety of antigens including highly conserved human antigens.

Type
Private
HQ
Cambridge, CB22 3AT, GB
Founded
2009
Employees
100 (est)+2%
Kymab was founded in 2009 and is headquartered in Cambridge, CB22 3AT, GB

Kymab Locations

Cambridge, CB22 3AT, GB

Kymab Metrics

Kymab Summary

Founding Date

2009

Total Funding

$220 M

Latest funding size

$100 M

Time since last funding

2 months

Investors

We estimate that Kymab's latest funding round in November 2016 was $100 M. In total, Kymab has raised $220 M

Kymab Company Life

You may also be interested in